ductal carcinoma, breast
Jump to navigation
Jump to search
Introduction
See breast cancer.
Epidemiology
most frequent histologic type (70%)
Genetics
- see breast cancer
- overexpression of NEK8
- specifically implicated genes:
Management
- ductal carcinoma in situ
- surgical excision with negative margins by histopathology
- adjuvant radiation therapy cuts recurrence rate in half
- adjuvant aromatase inhibitor for postmenopausal women[1]
- adjuvant tamoxifen for 5 years for premenopausal women[1]
- axillary node dissection is not indicated
- incidence of lymph node metastases is 2-3%
- invasive ductal carcinoma
- modified radical mastectomy (most common surgery)
- breast-conserving therapy
- lumpectomy
- partial (segmental) mastectomy or quadrantectomy
- radiation therapy
- sentinel lymph node biopsy
- tamoxifen vs aromatase inhibitor for estrogen receptor- positive tumor after lumpectomy & radiation therapy to reduce risk of local recurrence &/or 2nd primary
- see breast cancer
More general terms
More specific terms
References
- ↑ 1.0 1.1 1.2 Medical Knowledge Self Assessment Program (MKSAP) 11, 16. American College of Physicians, Philadelphia 1998, 2012
- ↑ Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 666
- ↑ Smith BD et al, Effectiveness of radiation therapy in older women with ductal carcinoma in situ. J Natl Cancer Inst 2006, 98:1302 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16985249
- ↑ Fisher B, Dignam J, Wolmark N et al Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999 Jun 12;353(9169):1993-2000. PMID: https://www.ncbi.nlm.nih.gov/pubmed/10376613
Patient information
breast ductal carcinoma patient information